BIOMAT Database Logo BIOMAT Database Logo

Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint. 2000

K Wachtell, and G Smith, and E Gerdts, and B Dahlöf, and M S Nieminen, and V Papademetriou, and J N Bella, and H Ibsen, and J Rokkedal, and R B Devereux
Copenhagen County University Hospital, Glostrup, Denmark. wachtell@dadlnet.dk

Abnormal left ventricular (LV) filling may exist in early stages of hypertension. Whether this finding is related to LV hypertrophy is currently controversial. This study was undertaken to assess relations between abnormal diastolic LV filling and LV geometry in a large series of hypertensive patients with electrocardiographic LV hypertrophy. M-mode, 2-dimensional, and pulsed Doppler echocardiographic recordings of mitral inflow velocity and isovolumetric relaxation time (IVRT) were obtained in 750 patients with stage I to III hypertension and LV hypertrophy determined by electrocardiography (sex-adjusted Cornell voltage duration criteria or Sokolow-Lyon voltage criteria) after 14 days of placebo treatment. The patients' mean age was 67+/-7 years and 44% were women. One hundred forty patients (19%) had normal LV geometric pattern, 79 (11%) had concentric remodeling, 342 (45%) had eccentric LV hypertrophy, and 189 (25%) had concentric LV hypertrophy. A normal LV filling pattern was found in 116 patients (16%), abnormal relaxation in 519 (69%), "pseudonormal" filling was found in 83 (11%), and a restrictive filling pattern in 32 (4%). Prolonged IVRT was associated with LV hypertrophy (p<0.01) as well as elevated relative wall thickness (p<0.05). A stronger difference (p<0.01) in IVRT was found between groups with and without LV hypertrophy. Multiple regression analysis revealed that increased LV mass correlated with prolonged IVRT, whereas LV mass and geometry were not associated with peak early LV filling velocity (E), peak atrial filling velocity (A) ratio or mitral valve E-peak deceleration time, although IVRT was found to be an independent correlate of E/A ratio and deceleration time. Thus, abnormal IVRT was highly prevalent in all LV geometric subgroups among hypertensive patients with electrocardiographic LV hypertrophy, even in those with normal LV geometry determined by echocardiography. We found that IVRT differed significantly among patient groups with different LV geometric patterns, primarily because of the association of IVRT to LV mass.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001783 Blood Flow Velocity A value equal to the total volume flow divided by the cross-sectional area of the vascular bed. Blood Flow Velocities,Flow Velocities, Blood,Flow Velocity, Blood,Velocities, Blood Flow,Velocity, Blood Flow
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005260 Female Females
D006352 Heart Ventricles The lower right and left chambers of the heart. The right ventricle pumps venous BLOOD into the LUNGS and the left ventricle pumps oxygenated blood into the systemic arterial circulation. Cardiac Ventricle,Cardiac Ventricles,Heart Ventricle,Left Ventricle,Right Ventricle,Left Ventricles,Right Ventricles,Ventricle, Cardiac,Ventricle, Heart,Ventricle, Left,Ventricle, Right,Ventricles, Cardiac,Ventricles, Heart,Ventricles, Left,Ventricles, Right
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Wachtell, and G Smith, and E Gerdts, and B Dahlöf, and M S Nieminen, and V Papademetriou, and J N Bella, and H Ibsen, and J Rokkedal, and R B Devereux
Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
November 2004, Expert opinion on pharmacotherapy,
K Wachtell, and G Smith, and E Gerdts, and B Dahlöf, and M S Nieminen, and V Papademetriou, and J N Bella, and H Ibsen, and J Rokkedal, and R B Devereux
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
December 1998, Hypertension (Dallas, Tex. : 1979),
K Wachtell, and G Smith, and E Gerdts, and B Dahlöf, and M S Nieminen, and V Papademetriou, and J N Bella, and H Ibsen, and J Rokkedal, and R B Devereux
Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
March 2002, Hypertension (Dallas, Tex. : 1979),
K Wachtell, and G Smith, and E Gerdts, and B Dahlöf, and M S Nieminen, and V Papademetriou, and J N Bella, and H Ibsen, and J Rokkedal, and R B Devereux
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
August 2003, Circulation,
K Wachtell, and G Smith, and E Gerdts, and B Dahlöf, and M S Nieminen, and V Papademetriou, and J N Bella, and H Ibsen, and J Rokkedal, and R B Devereux
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
January 2009, Blood pressure,
K Wachtell, and G Smith, and E Gerdts, and B Dahlöf, and M S Nieminen, and V Papademetriou, and J N Bella, and H Ibsen, and J Rokkedal, and R B Devereux
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
April 2008, Hypertension (Dallas, Tex. : 1979),
K Wachtell, and G Smith, and E Gerdts, and B Dahlöf, and M S Nieminen, and V Papademetriou, and J N Bella, and H Ibsen, and J Rokkedal, and R B Devereux
Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
August 2002, American journal of hypertension,
K Wachtell, and G Smith, and E Gerdts, and B Dahlöf, and M S Nieminen, and V Papademetriou, and J N Bella, and H Ibsen, and J Rokkedal, and R B Devereux
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
September 2004, Circulation,
K Wachtell, and G Smith, and E Gerdts, and B Dahlöf, and M S Nieminen, and V Papademetriou, and J N Bella, and H Ibsen, and J Rokkedal, and R B Devereux
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
March 2009, Journal of hypertension,
K Wachtell, and G Smith, and E Gerdts, and B Dahlöf, and M S Nieminen, and V Papademetriou, and J N Bella, and H Ibsen, and J Rokkedal, and R B Devereux
Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
January 2000, Hypertension (Dallas, Tex. : 1979),
Copied contents to your clipboard!